Pharma companies are increasingly exploring the use of digital twins to create “virtual patients”: data-rich simulations modeled from biological, clinical, behavioral, and pharmacological inputs. These virtual counterparts can be used to test interventions, predict drug responses, and optimize trial design, all before a single real-world patient is enrolled.
Pharma companies are piloting digital twins to streamline early-phase trials, potentially accelerating development timelines while lowering both financial and ethical costs. Their work illustrates what’s possible when simulation replaces speculation: fewer failed trials, faster go/no-go decisions, and less dependence on human testing during the riskiest stages of development.
While digital twins are powerful, they are not a replacement for traditional trials. They should be viewed as a tool to strengthen trial design and decision-making.
Their value lies in helping researchers stress-test protocols, anticipate risks, and refine strategies before engaging with real patients, whose voices and lived experiences remain central to medical progress.
Read more | CLINICAL LEADER